Sales up at Janssen in Japan despite mainstay challenges
This article was originally published in Scrip
Total sales at Janssen Pharmaceutical in Japan rose by 3% to ¥80.5 billion ($868.4 million) in calendar 2009, despite challenging conditions for several mainstay products.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.